Pharma BD Deal Intelligence
Sanofi's $425 million expanded mRNA bet with Translate Bio paid off as a platform play — leading to a full $38/share buyout — but Sanofi later deprioritized the COVID candidate MRT5500 and wound down the seasonal-flu mRNA effort it was meant to fund.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi paid $425 million upfront — $300M cash plus $125M equity — to expand its 2018 mRNA collaboration with Translate Bio to cover the entire infectious…
Sanofi has dramatically expanded its mRNA vaccine collaboration with Translate Bio, agreeing to pay $300 million in cash plus $125 million in equity to broaden…
Sanofi today announced an agreement to acquire its mRNA vaccine partner Translate Bio for $38 per share in cash, valuing the deal at approximately…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Sanofi Pasteur and Translate Bio closed an expanded collaboration and licensing agreement covering mRNA vaccines for all infectious diseases (broadening the 2018 deal that had covered up to five pathogens). Translate Bio received $425M ($300M cash upfront + $125M equity) with eligibility for up to $1.9B in milestones plus tiered royalties. The collaboration proved the foundation for Sanofi's full acquisition of Translate Bio: announced Aug 3, 2021 at $38/share (~$3.2B equity value) and completed Sep 14, 2021. Sanofi subsequently deprioritized the COVID-19 candidate MRT5500 and pivoted the Translate Bio mRNA platform toward seasonal influenza and other pathogens; the seasonal-flu mRNA effort was later wound down.
Assessment window: 5yr post-close.
330M US cases/yr · $35.0B Global vaccines market 2020 (USD MM, IQVIA) · 80000 Projected global vaccines market 2030 (USD MM)
Infectious diseases collectively cause over 13 million deaths annually worldwide (WHO 2020), with vaccine-preventable diseases representing the largest commercial opportunity in the global vaccines market — valued at approximately $35B in 2020 (IQVIA) and projected to grow to $80B+ by 2030 driven by COVID-19, RSV, seasonal influenza, and pandemic preparedness investments. The 2020 mRNA platform inflection arose from rapid clinical validation of Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273 against SARS-CoV-2, which demonstrated >94% efficacy in Phase 3 trials and earned FDA EUAs in December 2020 — establishing mRNA as the fastest, most flexible vaccine modality for novel pathogens. Beyond COVID-19, key infectious disease targets with sustained commercial pull include seasonal influenza (estimated 12,000-52,000 US deaths/year, $5-7B global vaccine market), respiratory syncytial virus (RSV, 14,000 US deaths/year in older adults, $5-10B projected market by 2030), cytomegalovirus (CMV, congenital infection ~30,000 US births/year), Zika, Lassa fever, dengue, Epstein-Barr virus and emerging pandemic threats (Disease X). The Sanofi Pasteur-Translate Bio collaboration expanded an existing 2018 deal (which had covered up to five undisclosed pathogens) to all infectious diseases — positioning Sanofi to challenge Moderna and Pfizer/BioNTech in mRNA vaccines using Translate Bio's MRT lipid nanoparticle delivery platform.
The mRNA infectious disease vaccine landscape was reshaped during 2020 by COVID-19 success but remained competitively crowded across non-COVID indications. Direct mRNA platform competitors include Moderna (mRNA-1273 COVID-19, mRNA-1647 CMV Phase 2, mRNA-1010 seasonal flu Phase 1, mRNA-1345 RSV Phase 2/3, plus EBV/HMPV/PIV3 candidates), Pfizer/BioNTech (BNT162b2 COVID-19, BNT161 influenza partnered with Pfizer Aug 2018, BNT164 TB), CureVac (CVnCoV COVID-19 Phase 3, plus rabies/flu candidates), GSK/CureVac (announced parallel July 2020 deal for 5 mRNA programs), Arcturus Therapeutics (LUNAR-COV19 self-amplifying mRNA, Phase 2), and Providence Therapeutics. Translate Bio differentiated through its MRT lipid nanoparticle platform optimized for non-COVID respiratory pathogens (cystic fibrosis, OTC deficiency in liver — non-vaccine programs continued). Adjacent non-mRNA vaccine technologies include AstraZeneca/Oxford (ChAdOx1 viral vector), Janssen Ad26 platform (Ad26.COV2.S COVID, Ebola), Novavax (NVX-CoV2373 protein subunit + Matrix-M adjuvant), Sanofi Pasteur's pre-existing protein vaccines (Fluzone, Menactra, Pentacel), and Merck's recombinant platforms (Gardasil 9, Pneumovax, M-M-R II). Saponin-based and protein nanoparticle adjuvant systems from Novavax, Dynavax (CpG 1018) and SaNOtize were emerging as differentiators in non-mRNA platforms. The Sanofi-Translate Bio deal effectively gave Sanofi an mRNA infectious disease franchise that did not require building internal capability — though Moderna's first-mover advantage and Pfizer/BioNTech's COVID-19 dominance were already entrenched.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Translate Bio Inc. (this deal) | 2020 | $2.3B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2020 deals · Sanofi SA deals · Infectious Disease deals